Brief: Reata Pharmaceuticals, Inc. reports Q2 results
08/08/2022 11:53
Aug 8 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2022
FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT
PROGRAMS
* Q2 GAAP NET LOSS PER SHARE $2.02
* Q2 NON-GAAP LOSS PER SHARE $1.36
* REATA PHARMACEUTICALS- REAFFIRMS EXISTING CASH & CASH
EQUIVALENTS, MARKETABLE DEBT SECURITIES TO BE SUFFICIENT TO FUND
OPERATIONS THROUGH END OF 2024
* Q2 EARNINGS PER SHARE VIEW $-2.02 -- REFINITIV IBES DATA
Source text for Eikon: ID:nBwH0Hy8a
Further company coverage: RETA.O
(Reporting by Priyamvada C)
((Priyamvada.C@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer